

A systematic review of pharmacist input in the screening, management and prevention of metabolic syndrome

Rana Al Adawi¹, Derek Stewart², Cristin Ryan³, Antonella Tonna².
Hamad Medial Corporation¹, Robert Gordon University², Trinity College Dublin³.

Available from: http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018089862

Background:

Metabolic syndrome (MetS) is a cluster of factors that increase the risk of cardiovascular disease and include diabetes, abdominal obesity, elevated triglycerides, low high-density lipoprotein cholesterol and high blood-pressure. A patient is considered to have MetS if 3 out of 5 factors are present ¹.

Purpose:

To critically appraise, synthesise, and present the available evidence on: the types and impact of pharmacist input in MetS, to characterize the populations who would benefit most and to describe facilitators and barriers.

Methods:

- ❖ **Search string:** Pharm*, "Metabolic syndrome*", "Syndrome X", "Insulin resistance syndrome*", "Dysmetabolic syndrome*", "Hypertriglyceridemic waist*", "Obesity syndrome*", "Metabolic Cardiovascular Syndrome", "Reaven Syndrome X", "Atherothrombogenic syndrome"
- ❖ **Databases:** Medline, Cumulative Index of Nursing and Allied Health Literature (CINAHL), International Pharmaceutical Abstracts (IPA), Cochrane Database of Systematic Reviews
- ❖ **Included studies:** Peer-reviewed papers published in English from 2008; all study designs were included
- ❖ **Papers assessed :** By two reviewers for methodological quality
- ❖ **Critically appraised:** Data extracted using standardized tools²

Results:





Figure 1 – Search flowchart as an adapted PRISMA diagram³

Children and adolescent



Populations that would benefit the most




Figure 2 – The population who would benefit the most from the pharmacist input in MetS




Figure 3– Some facilitators and barriers of pharmacist-led implementation




Figure 4 – Impact of the pharmacist input



Disclosure: None of the authors of this study have to disclose any possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this study.
Correspondence to: Rahmed4@hamad.qa

References:
1. Alberti, G., Zimmet, P., Shaw, J. and Grundy, S.M., 2006. The IDF consensus worldwide definition of the metabolic syndrome. Brussels: International Diabetes Federation, 23(5), 469-80.
2. Nhlbi.nih.gov. (2018). Study Quality Assessment Tools | National Heart, Lung, and Blood Institute (NHLBI). [online] Available at: <https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools> [Accessed 10 Sep. 2018].
3. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine. 2009; 6(7):e1000097.